GlassScriptPhysician profile
Brandon D Pomeroy
NPI 1619927720
$1,002.94
in general payments reported to CMS, 2019-2025
24 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $35.10 · 2021: $207 · 2022: $159 · 2023: $71.69 · 2024: $38.73 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.25 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $134.29 | 2025 | |
| Abbvie INC. | $100.01 | 2021-2023 | |
| Convatec INC. | $67.94 | 2019-2023 | |
| Janssen Biotech, INC. | $62.25 | 2020-2022 | |
| Travere Therapeutics, INC. | $62.04 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $57.61 | 2019 | |
| Progenics Pharmaceuticals, INC. | $51.83 | 2023-2025 | Pylarify |
| Urogen Pharma, INC. | $46.75 | 2024-2025 | |
| Rochester Medical Corporation | $44.51 | 2019-2021 | |
| Astellas Pharma US INC | $37.34 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Myriad Genetic Laboratories, INC. | $34.17 | 2021 | |
| Pfizer INC. | $34.12 | 2022 | |
| Endo Pharmaceuticals INC. | $32.47 | 2021-2022 | |
| Olympus America INC. | $31.94 | 2019-2025 | Itind System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28.40 | 2025 | Rivfloza |
| Boston Scientific Corporation | $26.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.65 | 2025 | Adstiladrin |
| Axonics, INC. | $19.05 | 2024 | Bulkamid, Axonics |
| Dendreon Pharmaceuticals LLC | $16.86 | 2019 | |
| Coloplast Corp | $15.65 | 2022 | |
| Mission Pharmacal Company | $15.45 | 2021 | |
| Laborie Medical Technologies Corp. | $14.35 | 2025 | |
| Blue Earth Diagnostics | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Pomeroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.